Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin.
暂无分享,去创建一个
V. Soto-Cerrato | R. Pérez-Tomás | G. Scheffer | Beatriz Montaner | George L Scheffer | Ricardo Perez-Tomas | Vanessa Soto-Cerrato | Esther Llagostera | B. Montaner | Esther Llagostera
[1] G. Loo,et al. Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. , 2004, Biochemical pharmacology.
[2] M. Péč,et al. Induction of apoptosis in estrogen dependent and independent breast cancer cells by the marine terpenoid dehydrothyrsiferol. , 2003, Biochemical pharmacology.
[3] R. Vossen,et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.
[4] S. B. Han,et al. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. , 1998, International journal of immunopharmacology.
[5] E. Slee,et al. To die or not to die: how does p53 decide? , 2004, Oncogene.
[6] A. Thor,et al. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. , 2001, Cancer research.
[7] J. Schellens,et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. , 2000, Cancer research.
[8] D. Green. Apoptotic Pathways The Roads to Ruin , 1998, Cell.
[9] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[10] H. Kamata,et al. A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. , 1997, Biochemical and biophysical research communications.
[11] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[12] R. Pérez-Tomás,et al. Activation of protein kinase C for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. , 2002, Biochemical pharmacology.
[13] Alan G. Porter,et al. Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.
[14] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[15] T. Litman,et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.
[16] P. Borst,et al. Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.
[17] H. Hirata,et al. Cycloprodigiosin hydrochloride, a H+/Cl− symporter, induces apoptosis in human breast cancer cell lines , 2000, Journal of Cancer Research and Clinical Oncology.
[18] R. Pérez-Tomás,et al. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. , 2003, Histology and histopathology.
[19] J. Schellens,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.
[20] J. Holden,et al. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. , 2003, Biochemical pharmacology.
[21] G. Pons,et al. Aspirin induces apoptosis through mitochondrial cytochrome c release , 2000, FEBS letters.
[22] H. Hirata,et al. Cycloprodigiosin hydrochloride, H+/CL– symporter, induces apoptosis and differentiation in HL‐60 cells , 2000, International journal of cancer.
[23] A. Mantovani,et al. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. , 1997, Journal of immunology.
[24] John Calvin Reed,et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. , 2000, Cancer research.
[25] D. Colomer,et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia , 2003, Leukemia.
[26] G. Salvesen,et al. Caspases: Intracellular Signaling by Proteolysis , 1997, Cell.
[27] J. Menéndez,et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. , 2001, European journal of cancer.
[28] S. Pal,et al. Curcumin induces apoptosis in human breast cancer cells through p53‐dependent Bax induction , 2002, FEBS letters.
[29] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[30] S. Srinivasula,et al. Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.
[31] G. Hortobagyi,et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. , 2001, The oncologist.
[32] R. Pérez-Tomás,et al. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. , 2001, Histology and histopathology.
[33] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[35] E. Giralt,et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines , 2000, British journal of pharmacology.
[36] T. Druley,et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.
[37] Y. Jeon,et al. Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. , 2001, The Journal of pharmacology and experimental therapeutics.
[38] P. Gnocchi,et al. Synthesis and immunosuppressive activity of novel prodigiosin derivatives. , 2000, Journal of medicinal chemistry.
[39] J. Trent,et al. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. , 1991, British Journal of Cancer.